Key result
Metoprolol cuts CV mortality and morbidity by ~20% in patients with cardiovascular diseases.
Why the study?
Cardiovascular diseases are the major cause of health problems and death worldwide, prompting a review of the efficacy of Metoprolol and Apixaban in their treatment.
Do Metoprolol and Apixaban reduce cardiovascular mortality/morbidity in patients with cardiovascular diseases?
Meta-Analysis (n=33,312)
Do Metoprolol and Apixaban reduce cardiovascular mortality/morbidity in patients with cardiovascular diseases?
This meta-analysis indicates that Metoprolol significantly reduces cardiovascular mortality and morbidity, while the findings for Apixaban were not statistically significant.
Answers are grounded in this paper and cite their sources.
Supports metoprolol for CV risk reduction in CVD patients; reinforces benefit in meta-analysis while apixaban data remain inconclusive.
Cardiovascular diseases (CVDs) are the major cause of health problems and death worldwide. To review the efficacy of Metoprolol and Apixaban in the treatment of cardiovascular diseases by meta-analysis studies. Various databases like PubMed, SciELO, Scopus, Google Scholar, and ResearchGate were used to collect the related studies that were published in English during the years 1980-2013. Only Random Clinical Trials (RCT) were included in this analysis. Risk bias assessment was according to the Cochrane Handbook for Systemic Reviews of the Interventions 6.4. Meta-analysis was done with the help of RevMan 5.4 software. A total of 10 (one study with different drug concentrations) related articles with 33312 patients were selected for this meta-analysis. In the Metoprolol-treated observation group of patients, the rate of cardiovascular mortality/morbidity [M.H=0.80,95%CI=0.67-0.95, Z=2.5, and P=0.01] was lower and in Apixaban-treated patients [M.H=0.32,95%CI=0.08-1.19, Z=1.7 and P=0.09] the rate of cardiovascular mortality/morbidity were higher and the difference was noted. It's clear that Apixaban and Metoprolol have a great role in treating cardiovascular diseases. The authors however acknowledge the presence of publication bias and limitations stemming from small sample sizes in some studies, demonstrating a critical and unbiased approach to analysis. Furthermore, it wisely calls for future research endeavors with larger sample sizes, contributing to the ongoing enhancement of treatments for cardiovascular diseases. This balanced and forward-looking analysis consolidates the importance of pharmaceutical interventions in managing cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Mavila et al. (2024) conducted a meta-analysis in Cardiovascular diseases (n=33,312). Metoprolol and Apixaban was evaluated on Cardiovascular mortality/morbidity (M.H 0.80, 95% CI 0.67-0.95, p=0.01). Metoprolol treatment was associated with a lower rate of cardiovascular mortality and morbidity in patients with cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: